1-氮杂金刚烷-4-甲腈 | 1047675-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-氮杂金刚烷-4-甲腈
• 英文名称: 2-cyano-5-azaadamantane
• 英文别名: 1-azaadamantane-4-carbonitrile；exo-4-cyano-1-azaadamantane；1-azatricyclo[3.3.1.13,7]decane-4-carbonitrile；(4r)-1-Azatricyclo[3.3.1.13,7]decane-4-carbonitrile
• CAS: 1047675-37-5
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: BABMIZCGANKZIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氮杂金刚烷-4-甲腈 在 sodium hydride 作用下， 以 苯 为溶剂， 反应 8.0h， 生成 1-Allyl-4-(allyloxy-phenyl-methylene)-1-azonia-tricyclo[3.3.1.1^3,7]decane; bromide
  参考文献：
  名称：

  Face Selection in Additions to the Trigonal C2 Site in Quaternized 5-Azaadamantane Derivatives

  摘要：

  The quaternary N-allyl bromide salt 5 of allyl alpha-[2-(5-azaadamantylidene)]benzyl ether upon warming gave the Claisen rearrangement products 6 is the ratio E/Z = 93:7. The epoxidation of the N-oxide 8 of 2-methylene-5-azaadamantane 7 with m-CPBA gives rise to the two diastereomeric epoxides 9 in the ratio E/Z = 19:81. Reaction of the methyl iodide salt of this olefin with bromine in water produces the E- and Z-dibromides 10 in the ratio 74:26 as well as the corresponding glycols 12 in the ratio 86:14. The same reaction in methanol gives the E- and Z-isomers of 10 alone, in the ratio of 35:65. The interpretation is that, in all of these reactions, the trigonal carbon preferably undergoes addition at that face which is antiperiplanar to the more electron-rich vicinal bonds, and does so by margins substantially in excess of those observed with the corresponding 5-fluoroadamantanes. This fact lends further strength to our previously drawn conclusion that hyperconjugative transition state stabilization is the principal factor in the electronic component of face selection.

  DOI：

  10.1021/ja00151a005
• 作为产物：
  描述：

  5-氮杂金刚烷-2-酮 、 对甲基苯磺酰甲基异腈 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 以0.38 g (38%)的产率得到1-氮杂金刚烷-4-甲腈
  参考文献：
  名称：

  4-aminomethyl-1-azaadamantane derived benzamides

  摘要：

  本发明涉及以下结构的化合物：##STR1## 或其药学上可接受的盐，其中Z选自以下组中的一种：##STR2##

  公开号：

  US05643917A1

文献信息

• COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION
  申请人：Xu Lifeng

  公开号：US20140045779A1

  公开（公告）日：2014-02-13

  This invention relates with anti-tumor activities of new compounds containing an adamantyl group or analogs thereof. The invention also relates with the medication applications of anti-tumor and other diseases by this kind of compounds with the combination of S, P, T structures containing adamantyl group and the formation of stereoisomer, tautomers, prodrug, pharmaceutically acceptable salts, complex salts or solvates to their anticancer application and anticancer agents, which have the following general formula:

  这项发明涉及含有金刚烷基团或其类似物的新化合物的抗肿瘤活性。该发明还涉及利用这种含有金刚烷基团的S、P、T结构的化合物与立体异构体、互变异构体、前药、药用盐、复杂盐或溶剂化物的结合来治疗抗肿瘤和其他疾病的药物应用，这些抗肿瘤剂具有以下一般公式：
• [EN] 1-AZAADAMANTANE DERIVATIVES AS 5-HT AGONISTS OR ANTAGONISTS<br/>[FR] DERIVES DE 1-AZAADAMANTANE UTILISES COMME AGONISTES OU ANTAGONISTES DE 5-HT
  申请人：G.D. SEARLE & CO.

  公开号：WO1994002482A1

  公开（公告）日：1994-02-03

  (EN) This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of (a) and (b), R1 is alkoxy of one to six carbon atoms; R2, R3, R4 and R5 are the same or different and are selected from the group consisting of hydrogen, halogen, CF3, hydroxy, alkoxy of one to six carbon atoms, acyl of two to seven carbon atoms, amino, amino substituted by one or two alkyl groups of one to six carbon atoms, C2-C7 acylamino, aminocarbonyl, aminosulfone optionally substituted by one or two alkyl groups of one to six carbon atoms, C1-C6 alkylsulfone and nitro; m is 1 or 2; X is 0 or NR7; and R7 is hydrogen or alkyl of 1 to 6 carbon atoms.(FR) L'invention se rapporte à des composés de la formule (I) ou à un sel pharmaceutiquement acceptable de ce composé, Z étant choisi dans le groupe composé de (a) et (b) dans lequel R1 représente alcoxy contenant un à six atomes de carbone; R2, R3, R4 ry R5 sont identiques ou différents et sont choisis dans le groupe comprenant hydrogène, halogène, CF3, hydroxy, alcoxy contenant un à six atomes de carbone, acyle contenant deux à sept atomes de carbone, amino, amino substitué par un ou deux groupes alkyle contenant un à six atomes de carbone, C2-C7 acylamino, aminocarbonyle, aminosulfone éventuellement substitué par un ou deux groupes alkyle contenant un à six atomes de carbone, C1-C6 alkylsulfone et nitro; m vaut 1 ou 2; X représente 0 ou NR7; et R7 représente hydrogène ou alkyle contenant 1 à 6 atomes de carbone.

  这项发明涉及公式（I）的化合物或其药学上可接受的盐，其中Z选择自（a）和（b）组成的群，R1是含有一到六个碳原子的烷氧基；R2、R3、R4和R5相同或不同，选择自氢、卤素、CF3、羟基、含有一到六个碳原子的烷氧基、含有二到七个碳原子的酰基、氨基、一或两个烷基含有一到六个碳原子的取代氨基、C2-C7酰胺基、氨基甲酰基、氨基磺酰基（可选地取代一或两个烷基含有一到六个碳原子）、C1-C6烷基磺酰基和硝基；m为1或2；X为0或NR7；R7为氢或含有1到6个碳原子的烷基。
• Aminomethyl Azaadamantane Derivatives and Methods of Use Thereof
  申请人：Shi Lei

  公开号：US20080262023A1

  公开（公告）日：2008-10-23

  The invention relates to compounds that are substituted aminomethyl azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.

  该发明涉及取代氨甲基氮杂金刚烷衍生物化合物，包括这种化合物的组合物以及使用这种化合物和组合物的方法。
• AZA-BRIDGED-RING COMPOUND
  申请人：Nagashima Shinya

  公开号：US20100105658A1

  公开（公告）日：2010-04-29

  [Problems] Provided is a compound which has an antagonistic action on a muscarinic M 3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [Means for Solving Problems] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M 3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M 3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M 3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.

  【问题】提供了一种具有抗胆碱能M3受体拮抗作用的化合物，可作为预防和/或治疗慢性阻塞性肺疾病（COPD）、哮喘等炎症性疾病的活性成分。 【解决问题的手段】本发明人对具有抗胆碱能M3受体结合作用的化合物进行了研究，发现一种氮杂环桥合环化合物或其盐具有抗胆碱能M3受体结合作用，从而完成了本发明。本发明的氮杂环桥合环化合物具有抗胆碱能M3受体结合作用，并可用作预防和/或治疗慢性阻塞性肺疾病（COPD）、哮喘等炎症性疾病的预防和/或治疗剂。
• Aminomethyl azaadamantane derivatives and methods of use thereof
  申请人：Abbott Laboratories

  公开号：US08168791B2

  公开（公告）日：2012-05-01

  The invention relates to compounds that are substituted aminomethyl azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.

  本发明涉及一种取代氨甲基氮杂莠烷衍生物的化合物，包括含有该化合物的组合物，以及使用该化合物和组合物的方法。